We used the T cell inflamed immune signature, composed of active IFN-γ signaling, cytotoxic effector, and antigen presentation molecules, and T cell active cytokines that were previously sequentially validated to predict response to standard immunotherapy in HNSCC, as well as other tumor types (15). Here, IFNG is linked to head and neck squamous cell carcinoma.